Who
D. Ryan Daws
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, enGene Therapeutics; Chief Financial Officer, Concert Pharmaceuticals.
In numbers
- Trades disclosed
- 8
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 19 Feb 2014
- Last trade
- 30 Jan 2026
- Last filed
- 3 Feb 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 30 Jan 2026filed 3 Feb 2026 | ENGN enGene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —220,000 at $0.00 | filing |
| 30 Jan 2026filed 3 Feb 2026 | ENGN enGene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —220,000 at $0.00 | filing |
| 29 Jan 2025filed 31 Jan 2025 | ENGN enGene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —280,000 at $0.00 | filing |
| 30 Nov 2023filed 4 Dec 2023 | ENGN enGene Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —232,000 at $0.00 | filing |
| 4 Jan 2017filed 6 Jan 2017 | Concert Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —82,500 at $0.00 | filing |
| 7 Jan 2016filed 8 Jan 2016 | Concert Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 10 Jun 2014filed 12 Jun 2014 | Concert Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 19 Feb 2014filed 19 Feb 2014 | Concert Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —123,893 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.